What You Should Know:
– Absci Corporation, a leader in generative AI drug creation, today announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop up to six novel cancer therapeutics.
– By combining Absci’s AI platform with MSK’s renowned cancer research expertise, the partnership aims to accelerate the discovery and development of new treatments for this devastating disease.
Absci’s Integrated Drug Creation Platform
Absci’s Integrated Drug Creation™ platform will be instrumental in identifying and optimizing potential drug candidates. MSK will contribute its deep understanding of cancer biology to guide the discovery process. The collaboration is expected to yield promising targets for preclinical development by the end of 2024.
This partnership marks a significant milestone for Absci, building upon its growing portfolio of collaborations with leading pharmaceutical companies and research institutions. The company has secured nearly $1 billion in drug discovery deals over the past year, including partnerships with AstraZeneca and Almirall.
Absci’s commitment to leveraging AI for drug discovery is exemplified by its internal pipeline, which includes ABS-101, a potential best-in-class anti-TL1A antibody. With a growing number of collaborations and a robust internal pipeline, Absci is positioned to play a pivotal role in addressing unmet medical needs in oncology and beyond.
“MSK has an incredible record of groundbreaking translational and clinical innovations in oncology, ” said Sean McClain, Founder & CEO of Absci “By combining MSK’s research expertise with our generative AI drug creation platform, we have the potential to unlock critical advances toward treating this devastating disease.”
